Please assess the completion status of the following clinical trial:

Trial Title: PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized either in the ICU or ward, with a diagnosis of pneumonia, complicated abdominal infections, or complicated urinary tract infection using the protocol-defined Guidelines for Diagnosis~Exclusion Criteria:~* Pregnant or lactating females~* Allergies to Doripenem or its derivatives~* Infected by a bacteria that is resistant to Doripenem~* Taking probenecid~* Severe allergies to other antibiotics like penicillins, cephalosporins, or carbapenems~* Severe kidney disease, in an unstable disease state and assessed as unlikely to survive until the study follow up period~* Signs of severe sepsis with treatment failure with other carbapenems, who received other carbapenem within 2 weeks before first dose of study drug, and who has any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: OTHER): doripenem 500mg vial by injection every 8 hours for 5 to 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).